Desmopressin vs BI 456906
Head-to-head comparison of Desmopressin (1-Deamino-8-D-arginine vasopressin) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Desmopressin | BI 456906 |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | 1-Deamino-8-D-arginine vasopressin | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 1069.22 Da | N/A |
| Half-Life | 1.5-3 hours | Approximately 1 week |
| Amino Acids | 9 | N/A |
| Typical Dose | 10-40 mcg intranasal | Trial-dependent; weekly SC dosing |
| Route | Intranasal/Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 35 | 10 |
| Research Status | Clinical | Clinical |
Desmopressin Benefits
- ✓memory consolidation
- ✓reduced pressor burden
- ✓recall support
- ✓short-term learning
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
Desmopressin Dosing
intranasal research dosing|10-40 mcg or IU-equivalent studies|single-dose protocols
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
Desmopressin Side Effects
- ⚠hyponatremia
- ⚠headache
- ⚠nasal irritation
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
Desmopressin
The literature is mixed, but desmopressin has shown memory-related effects in selected populations and experimental paradigms. Its cognitive effects are usually discussed as a vasopressin-pathway probe rather than a primary nootropic.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.